¡Ya estamos en ! Descubre más
294.66 USD
+1.43
0.49%
Al cierre Actualizado 16 oct, 4:00 p.m. EDT
Antes de la apertura del mercado
Después del cierre del mercado
295.00
+0.34
0.12%
1 día
0.49%
5 días
6.26%
1 mes
3.48%
3 meses
-11.03%
6 meses
-12.92%
En lo que va del año
-15.37%
1 año
-20.2%
5 años
12.44%
10 años
159.45%
 

Acerca de: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.

Empleados: 56,000

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 39.1%
Neutral 56.5%
Negativo 4.3%
Neutral
GlobeNewsWire
ayer
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) investors concerning the Company's possible violations of the federal securities laws.
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Neutral
PRNewsWire
ayer
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Neutral
GlobeNewsWire
ayer
Stryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
Stryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Neutral
GlobeNewsWire
anteayer
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) on behalf of investors concerning the Company's possible violations of federal securities laws.
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Neutral
PRNewsWire
anteayer
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Stryker has received FDA 510(k) clearance for Sonopet ® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility.
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Neutral
GlobeNewsWire
hace 3 días
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Positivo
Seeking Alpha
hace 4 días
Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story
Stryker rebounded in 2Q26, with operating momentum restored after the prior quarter's cybersecurity disruption. 2Q26 sales rose 9.4% YoY to ~$6.6 billion; organic growth reached ~9%, demonstrating resilience despite earlier headwinds. Adjusted EPS increased ~18% to $3.69, and operating margin expanded 170 bps to 27.4%, reflecting improved profitability.
Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story
Neutral
PRNewsWire
hace 8 días
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Neutral
GlobeNewsWire
hace 10 días
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Negativo
Investors Business Daily
hace 10 días
Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Stryker and Neogenomics stocks diverged Tuesday after the medtech companies announced their chief executives would soon step down.
Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Gráficos de precios implementados con Lightweight Charts™